Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $30.00 to $35.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price would indicate a potential upside of 148.76% from the stock’s previous close.
Several other equities research analysts have also issued reports on SRPT. William Blair reissued a “market perform” rating on shares of Sarepta Therapeutics in a research report on Friday, June 20th. Scotiabank raised shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target for the company in a research note on Friday, June 6th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday, June 25th. Wells Fargo & Company decreased their target price on Sarepta Therapeutics from $100.00 to $75.00 and set an “overweight” rating on the stock in a report on Tuesday, June 17th. Finally, Wolfe Research assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, June 17th. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus price target of $56.50.
Check Out Our Latest Report on Sarepta Therapeutics
Sarepta Therapeutics Stock Down 36.0%
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 EPS. Analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.
Institutional Investors Weigh In On Sarepta Therapeutics
A number of institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its stake in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after buying an additional 145 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Sarepta Therapeutics by 22.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company’s stock worth $773,000 after purchasing an additional 1,151 shares during the last quarter. Corient Private Wealth LLC bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $786,000. Xponance Inc. boosted its position in shares of Sarepta Therapeutics by 3.1% during the fourth quarter. Xponance Inc. now owns 18,713 shares of the biotechnology company’s stock valued at $2,275,000 after buying an additional 571 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in Sarepta Therapeutics by 19.1% in the 4th quarter. Teacher Retirement System of Texas now owns 25,412 shares of the biotechnology company’s stock worth $3,090,000 after buying an additional 4,076 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
- Five stocks we like better than Sarepta Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Why Pure Storage Is a Core Investment for the AI Era
- The How And Why of Investing in Oil Stocks
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- Golden Cross Stocks: Pattern, Examples and Charts
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.